| pubmed-article:2253653 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2253653 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2253653 | lifeskim:mentions | umls-concept:C0001792 | lld:lifeskim |
| pubmed-article:2253653 | lifeskim:mentions | umls-concept:C1708335 | lld:lifeskim |
| pubmed-article:2253653 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:2253653 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:2253653 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:2253653 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:2253653 | lifeskim:mentions | umls-concept:C0069772 | lld:lifeskim |
| pubmed-article:2253653 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2253653 | pubmed:dateCreated | 1991-1-24 | lld:pubmed |
| pubmed-article:2253653 | pubmed:abstractText | The pharmacokinetics of oxiracetam have been studied in eighteen elderly patients and in six healthy non-geriatric adults. A 800 mg single oral dose was administered in the morning of the first day and repeatedly, every 12 h, from day 2 evening to day 10 morning, to the elderly patients. The healthy non-geriatric adults were given a 800 mg single oral dose of oxiracetam. In healthy non-geriatric subjects after a single oral administration of 800 mg, the normalized plasma levels of oxiracetam for 1 mg/kg dose were similar to those already recorded after a 2000 mg single dose of oxiracetam. Therefore, there was no tendency towards non-linear pharmacokinetics of oxiracetam between 800 and 2000 mg single doses in healthy subjects. After the single oral dose, the mean area under the plasma concentration-time curve of oxiracetam in elderly patients was increased by a factor of two as compared to that observed in non-geriatric healthy subjects whereas the maximum concentration (Cmax) was almost not modified and slightly delayed. This can be explained by a slower absorption and elimination in the elderly patients. The highest oxiracetam levels were predominantly recorded in the oldest patients. The slower elimination (mean T1/2 = 12.3 h in elderly and 7.7 h in healthy subjects) could be attributed to a physiological decrease of the renal function. The volume of distribution was not significantly modified in the elderly patients.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:2253653 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2253653 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2253653 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2253653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2253653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2253653 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2253653 | pubmed:issn | 0378-7966 | lld:pubmed |
| pubmed-article:2253653 | pubmed:author | pubmed-author:DarragonTT | lld:pubmed |
| pubmed-article:2253653 | pubmed:author | pubmed-author:BeckHH | lld:pubmed |
| pubmed-article:2253653 | pubmed:author | pubmed-author:TheobaldWW | lld:pubmed |
| pubmed-article:2253653 | pubmed:author | pubmed-author:LecaillonJ... | lld:pubmed |
| pubmed-article:2253653 | pubmed:author | pubmed-author:DuboisJ PJP | lld:pubmed |
| pubmed-article:2253653 | pubmed:author | pubmed-author:CoppensHH | lld:pubmed |
| pubmed-article:2253653 | pubmed:author | pubmed-author:ReumondGG | lld:pubmed |
| pubmed-article:2253653 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2253653 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:2253653 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2253653 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2253653 | pubmed:pagination | 223-30 | lld:pubmed |
| pubmed-article:2253653 | pubmed:dateRevised | 2011-2-2 | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:meshHeading | pubmed-meshheading:2253653-... | lld:pubmed |
| pubmed-article:2253653 | pubmed:articleTitle | Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects. | lld:pubmed |
| pubmed-article:2253653 | pubmed:affiliation | Biopharmaceutical Research Center and Medical Department, Laboratoires CIBA-GEIGY, Rueil-Malmaison, France. | lld:pubmed |
| pubmed-article:2253653 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2253653 | pubmed:publicationType | Comparative Study | lld:pubmed |
